Unmet need is a huge driver in the development of oncology treatments. But when it comes to choosing the therapies that “make the cut,” it’s not that simple.
What are the risks involved? Where has efficacy been demonstrated in the treatment area and type? And the timeless question: who’s paying for it?
Jeff Bockman, Ph.D. , EVP & Oncology Practice Head at Cello Health BioConsulting, joins us to share his experience and break down the criteria and considerations of how therapies are chosen and developed.
Here are the show highlights
- Who are the players and decision-makers developing therapies? (3:18)
- How developers decide which therapies to pursue (15:34)
- How the element of risk complicates the goal of pursuing unmet needs (28:20)
- Pipeline activity, precision oncology, and more trends in biotech (34:24)
- Why we’ll see more “engineering of biology” in the next 5-10 years (39:28)
Stay connected with Working in Oncology on Apple Podcasts, Spotify, or our podcast website.
Check out these resources mentioned during the podcast:
Guest Bio
Jeffrey Bockman, PhD, is the EVP and Oncology Practice Head at Chello Health BioConsulting. Dr Bockman has extensive commercial and strategic perspectives on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at DH. He often speaks at conferences on scientific and commercial issues in cancer, biologics, and personalized medicine.
